Lupin acquires two respiratory segment brands from Sanofi – Healthcare News

Global pharma major Lupin Limited on Wednesday announced that its European hub entity, Lupin Atlantis Holdings SA, has completed the acquisition of two well-known brands, AaraneTM in Germany and NalcromTM in Canada and the Netherlands.

According to the company’s statement, the acquisition has been done along with the associated trademark rights, from Sanofi.

NalcromTM (sodium cromoglicate Oral) belongs to a group of medicines called anti-allergics. It is used to treat food allergies after adequate testing for sensitivity to specific allergens in conjunction with restricting the main allergens.

Bird Flu in Mexico: Man dies from World’s first human case of H5N2 bird flu-Know all about its causes, symptoms and treatment

Torrent Pharma signs non-exclusive patent agreement with Takeda for its novel drug to treat GERD in India

Aurigene opens its biologics facility to offer process development and clinical scale manufacturing capabilities

Beware of pigeon droppings! It can permanently damage your lungs; here’s how

Meanwhile, AaraneTM (sodium cromoglicate/reproterol hydrochloride pressurized inhalation) is a chromone complex indicated in symptomatic acute treatment of sudden asthma attacks (e.g., allergic forms or those triggered by exertion, stress or infections) and targeted prevention of exercise-induced asthma or in cases of foreseeable allergen contact.

The transaction aligns with Lupin’s strategy to grow its global presence in Specialty areas, where the company has a leading position, with high-quality products that are innovative or unique in the market, the company said in a statement.

This acquisition will enhance Lupin’s Respiratory business in Germany, by aiding in the expansion of the newly established franchise, following the introduction of LuforbecTM, it announced.

“This acquisition will strengthen our global position in treating patients suffering from diverse respiratory diseases and conditions, and it adds accretive assets in gastro-intestinal care that broaden our portfolio of branded products. We are committed to provide our customers and patients with the best products and services in the
market segments where we are present, improving the quality of life for millions of people around the world,” Dr. Fabrice Egros, President – Corporate Development, Lupin said in a statement.